Hyderabad-based pharma major Dr Reddys Laboratories today reported a net profit of Rs 503.49 crore for the quarter ended December 31, 2006, while its overall revenues crossed the one billion dollar mark on the back of two major acquisitions.The company said its total income (net of excise) of the at the end of the December quarter stood at Rs 1212.11 crore, while the same was recorded at Rs 532.22 crore for the quarter ended December 31, 2005, Dr Reddy's informed the BSE.
"For the first time in the history of Dr Reddys, we have crossed USD 1 billion in revenues. Starting as an API manufacturer addressing the Indian market over the last 22 years, Dr Reddys has grown into a vertically integrated global pharmaceutical company with activities spanning the entire pharmaceutical value chain," Dr Reddys CEO GV Prasad said.
The consolidated results of the current quarter include the results acquisitions of Germany's Betapharm and Roche group company, Industrias Quimicas Falcon de Mexico, therefore, not comparable with the previous period, DRL said.
Courtesy : expressindia.com
"For the first time in the history of Dr Reddys, we have crossed USD 1 billion in revenues. Starting as an API manufacturer addressing the Indian market over the last 22 years, Dr Reddys has grown into a vertically integrated global pharmaceutical company with activities spanning the entire pharmaceutical value chain," Dr Reddys CEO GV Prasad said.
The consolidated results of the current quarter include the results acquisitions of Germany's Betapharm and Roche group company, Industrias Quimicas Falcon de Mexico, therefore, not comparable with the previous period, DRL said.
Courtesy : expressindia.com